Core Viewpoint - Zevra Therapeutics, Inc. will report its corporate and financial results for Q4 and full year 2024 on March 11, 2025, and will host a conference call at 4:30 p.m. ET on the same day [1]. Group 1 - The company focuses on providing therapies for individuals with rare diseases, aiming to create transformational therapies where limited or no treatment options exist [3]. - Zevra employs unique, data-driven development and commercialization strategies to address complex drug development challenges [3]. - A link to the audio webcast of the conference call will be available on the "Events & Presentations" page of Zevra's website [2]. Group 2 - A replay of the conference call will be accessible for 90 days starting approximately at 5:30 p.m. ET on the same day [2]. - For further information, Zevra's website and social media platforms can be visited [4]. - Contact information for inquiries is provided, including a dedicated conference ID for the call [6].

Core Insights - Zevra Therapeutics, Inc. is focused on developing therapies for rare diseases with limited treatment options, aiming to provide life-changing therapeutics to affected individuals [2]. Company Events - Zevra's executive leadership team will participate in the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 10:30 a.m. ET, and the 37th Annual ROTH Conference on March 17, 2025, at 1:00 p.m. PT [1][5]. - Management will be available for one-on-one meetings with registered attendees at each conference [1]. Company Overview - Zevra combines science, data, and patient needs to create transformational therapies, overcoming complex drug development challenges [2]. - The company utilizes unique, data-driven development and commercialization strategies to make new therapies available to the rare disease community [2]. Communication Channels - For more information, Zevra can be followed on X (formerly Twitter) and LinkedIn, and additional details are available on their website [3].

Core Points - Zevra Therapeutics will receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposium, recognizing advancements in treating lysosomal diseases [2][3] - Eight abstracts related to MIPLYFFA have been accepted for presentation, including one selected for oral presentation by Dr. Eugen Mengel [1][4] Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on rare disease therapeutics, aiming to develop transformational therapies for diseases with limited treatment options [21] - The company emphasizes a data-driven approach to overcome drug development challenges and meet patient needs [21] Product Information - MIPLYFFA (arimoclomol) is indicated for treating neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged 2 years and older, in combination with miglustat [10] - The drug has received multiple designations from the FDA, including Breakthrough Therapy and Orphan Drug designations, highlighting its significance in treating NPC [9] Clinical Research and Presentations - The pivotal phase 3 trial of MIPLYFFA demonstrated that it halted disease progression compared to placebo over a one-year period, as measured by the NPC Clinical Severity Scale [9] - The WORLDSymposium will feature various presentations on MIPLYFFA, including efficacy results from a 12-month double-blind randomized trial [4][5][6] Event Participation - Zevra will participate in the WORLDSymposium taking place from February 3-7, 2025, in San Diego, CA, where attendees can visit their booth [7][8]

Core Points - Zevra Therapeutics, Inc. will be added to the Nasdaq Biotechnology Index effective December 23, 2024, which is part of the annual reconstitution of the Nasdaq indexes [1] - The addition to the Nasdaq Biotechnology Index is expected to enhance Zevra's visibility among biotech funds and portfolio managers, reflecting a transformational year for the company [2] Company Overview - Zevra Therapeutics is a commercial-stage company focused on developing therapies for rare diseases, aiming to address unmet medical needs [5] - The company employs unique, data-driven strategies for drug development and commercialization to overcome challenges in bringing new therapies to the rare disease community [5] Index Information - The Nasdaq Biotechnology Index tracks the performance of securities classified as biotechnology or pharmaceutical, calculated using a modified capitalization-weighted methodology [3] - Companies must meet specific eligibility criteria, including minimum market capitalization and average daily trading volume, to be included in the index [3]

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™, Zevra’s comprehensive patient support program, in place to address access barriers CELEBRATION, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that MIPLYFFA™ (MY-PLY-FAH) (arimoclomol), the first treatment approved by the U.S. Food an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-36913 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other J ...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Nichol Ochsner - VP, IR & Corporate Communications Neil McFarlane - President & CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer & EVP, Business Development Conference Call Participants Jason Butler - JMP Securities Louise Chen - Cantor Fitzgerald Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Sumant Kulkarni - Canaccord Genuity Oren Livnat - H.C ...

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -56.82%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.47 per share when it actually produced a loss of $0.48, delivering a surprise of -2.13%.Over the last four quart ...

Exhibit 99.1 Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher Company ends quarter with cash, cash equivalents and investments of $95.5 million Company to host conference call and webcast today, Nov. 12, 2024, 4:30 p.m. ET CELEBRATION, Fla., Nov. 12, 2024 -- Zevra Therapeutics, In ...

Data show that the NPCCSS swallow score reflects the patient’s level of dysfunction Study indicates that a change in score reflects actual improvement or worsening in a patient’s swallowing function CELEBRATION, Fla., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological ...